Insmed, Inc. $INSM Stock Purchased by Aberdeen Group plc

Key Points

• Aberdeen Group increased its Insmed stake by 40.3% in the third quarter, adding 232,466 shares to reach 809,903 shares, valued at about $92.4 million.
• Analysts’ consensus rating was “Moderate Buy,” with an average price target of $196.52; 23 analysts rated the stock a Buy.
• Insmed’s latest quarterly revenue rose 268.4% year over year to $524.43 million, beating estimates, while its loss of $0.46 per share was wider than expected.

Aberdeen Group plc raised its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 40.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 809,903 shares of the biopharmaceutical company's stock after purchasing an additional 232,466 shares during the period. Aberdeen Group plc owned 0.37% of Insmed worth $92,442,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Virginia Estate & Retirement Planning Advisors Inc. acquired a new position in shares of Insmed during the 3rd quarter worth approximately $29,000. SBI Securities Co. Ltd. lifted its stake in Insmed by 69.4% in the 3rd quarter. SBI Securities Co. Ltd. now owns 349 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 143 shares in the last quarter. CX Institutional acquired a new stake in Insmed during the 3rd quarter valued at $46,000. Harbor Investment Advisory LLC acquired a new stake in Insmed during the 2nd quarter valued at $52,000. Finally, Heritage Family Offices LLP acquired a new stake in Insmed during the 3rd quarter valued at $60,000.

Insider Buying and Selling

In other Insmed news, Director David Brennan sold 25,000 shares of the business's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the transaction, the director owned 39,238 shares in the company, valued at $4,865,512. The trade was a 38.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Truist Financial reissued a "buy" rating and issued a $195.00 price target (up from $185.00) on shares of Insmed in a report on Monday, August 10th. Mizuho set a $154.00 price objective on Insmed in a research report on Thursday, October 29th. Guggenheim decreased their price objective on Insmed from $205.00 to $201.00 and set a "buy" rating on the stock in a research note on Monday, November 2nd. Stifel Nicolaus set a $195.00 price objective on Insmed in a research report on Thursday, October 29th. Finally, Jefferies Financial Group reiterated a "buy" rating and set a $175.00 price objective on shares of Insmed in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $196.52.

Insmed Trading Up 2.6%

NASDAQ INSM traded up $3.09 during mid-day trading on Friday, hitting $121.16. The company's stock had a trading volume of 1,543,590 shares, compared to its average volume of 3,815,081. Insmed, Inc. has a 52-week low of $90.39 and a 52-week high of $212.75. The stock's fifty day simple moving average is $110.82 and its two-hundred day simple moving average is $123.37. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.86 and a quick ratio of 2.59. The firm has a market capitalization of $26.58 billion, a P/E ratio of -42.96 and a beta of 0.83.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). The company had revenue of $524.43 million for the quarter, compared to analyst estimates of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. The company's revenue for the quarter was up 268.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.75) EPS. Research analysts expect that Insmed, Inc. will post -1.86 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.